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1. Introduction
The principal changes from the European Society of 
Cardiology (ESC) chronic heart failure (HF) 2008 
guidelines relate to: (i) new definition of HF with 
reduced ejection fraction (HF-REF); (ii) expanded 
indication for mineralocorticoid (aldosterone) receptor antagonists 
(MRAs); (iii) indication for the sinus node inhibitor ivabradine; 
(iv)  expanded indication for cardiac resynchronisation therapy 
(CRT); (v) new information on the role of coronary revascularisation; 
and (vi) the role of ventricular assist devices.
2. Objective
The aim of this document is to highlight new changes with particular 
emphasis on areas that are relevant to South Africa. 
3. Definition and diagnosis of HF-REF
This guideline focuses on HF-REF; this term will replace the old 
reference ‘left ventricular systolic dysfunction’. The new cut-off 
ejection fraction (EF) for HF-REF is a left ventricular (LV) EF 
≤50%.
Randomised HF-REF trials have used an entry LVEF <35%. 
Most of the medications indicated in HF-REF, have been studied in 
trials where the EF was <35%. The definition of HF-REF, however, 
is an EF <50%. To avoid confusion between the inclusivity of the 
definition and the exclusivity of the randomised trials, we have 
taken a different approach to that of the ESC guideline.[1] We have 
recommended the use of these agents in symptomatic patients 
with HF-REF in general. The ESC guideline states that those 
patients with an EF of 35 - 50% are in a ‘grey area’, but taking 
into account the way clinical medicine is practised, the inherent 
variability in EF assessments, and the need to treat symptomatic 
patients with an EF in the abnormal range, this document 
recognises the clinical need for more definitive recommendations. 
Randomised clinical trials are a crucial, but not the only, guide in 
treating HF-REF patients. There always remain questions that are 
unanswered and groups of patients not studied, so prudent clinical 
decisions are required. 
3.1 Clinical definition
HF-REF is hereby defined as a syndrome in which patients have 
typical symptoms and signs resulting from an abnormality of LV 
function. It needs to be emphasised that HF is a syndrome and not 
a final diagnosis. Once the diagnosis of HF-REF has been made, it is 
important to establish the cause, in particular, a reversible cause, as 
well as a possible precipitating factor.
3.2 Diagnosis
3.2.1 Medical history
The patient’s medical history is important. The index of suspicion 
for HF-REF is increased in patients with suggestive symptoms and a 
prior history of hypertension, coronary artery disease, chemotherapy 
and in peri-partum women. Importantly, HF-REF can present in 
patients with no prior relevant history. 
3.2.2 Symptoms
Typical symptoms are breathlessness at rest or on exercise, fatigue, 
ankle and body swelling, orthopnoea, paroxysmal nocturnal 
dyspnoea and palpitations.
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3.2.2.1 Classifying severity of HF
Symptoms are used to classify the severity of effort intolerance 
in congestive HF. The New York Heart Association (NYHA) 
classification is recommended (Table 1). For common daily 
activities, use examples:
• Walking distance on level ground
• Class II – walk >2 blocks on the level
• Class III – walk <1 - 2 blocks
• Number of stairs climbed
• Class I – cope without symptoms
• Class II – climb 1 flight at normal pace
• Class III – climb <1 flight
• Tolerance of uphill
• Class I – cope without symptoms
• Class II – symptomatic on walking uphill
• Class III – symptomatic on any incline.
Limitations of the NYHA classification include:
• Ordinary physical activity is difficult to define and varies between 
individual patients and at different ages
• Mild symptoms do not imply minor cardiac dysfunction, and vice 
versa.
The NYHA functional class classification is useful to prognosticate, 
as functional capacity is a predictor of mortality. 
It also provides a guide to the patient’s previous best functioning 
so that therapy can be targeted at returning the patient to that level 
and better.
3.2.3 Signs 
These include tachycardia, tachypnoea, raised jugular venous 
pressure, peripheral oedema, right-sided pleural effusion and 
hepatomegaly. Objective evidence of a structural and/or functional 
abnormality of the LV at rest (displaced LV apex beat, left-sided S3 
gallop and cardiac murmurs).
3.2.4 Documentation of HF-REF
The echocardiogram provides immediate information on chamber 
size, ventricular function, LV wall thickness, valve structure and 
function, haemodynamics, pulmonary pressures and inferior vena 
caval congestion. 
A patient presenting with HF requires an echocardiogram as part 
of the diagnostic assessment. While it is recognised that this depends 
on local availability, echocardiography should be arranged during the 
index hospital admission.
4.  General diagnostic tests in patients 
with suspected HF-REF
4.1 Additional essential investigations
These include electrocardiogram (ECG), chest X-ray and B-type 
natriuretic peptides (BNPs)/N-terminal pro-B-type natriuretic 
peptide (NT-ProBNP) assays.
4.1.1 Resting ECG 
This may show sinus tachycardia (>100  bpm), bundle branch 
block patterns, heart block, previous myocardial infarction (MI), 
left ventricular hypertrophy, atrial fibrillation (AF), among other 
abnormalities. A normal ECG in all respects makes the diagnosis of 
HF-REF unlikely.
4.1.2 Chest X-ray 
This should be considered to detect/exclude lung disease. It may 
also identify pulmonary congestion/oedema and is more useful 
in patients with suspected HF in the acute setting. The important 
findings in chronic HF-REF are increased cardiothoracic ratio 
(>50%), right-sided pleural effusion, fluid in the fissures and upper-
lobe venous blood diversion.
4.1.3 Natriuretic peptides
Where the availability of echocardiography is limited, an alternative 
approach to the diagnosis of HF is to measure the blood concentration 
of BNPs. Two different assays are currently available: BNP and 
NT-ProBNP. A BNP <100 pg/ml or NT-ProBNP <300  pg/ ml (in 
patients who present acutely) and BNP <35  pg/ml or NT-ProBNP 
<125  pg/ml in patients who present (with chronic symptoms) 
virtually exclude the diagnosis of HF-REF. These tests are also useful 
in the follow-up of treated patients to clarify future presentations or 
persistence of symptoms.
Routine biochemical and haematological investigations are also 
important to determine renal function and potassium levels, to 
exclude anaemia (which can mimic or aggravate HF) and to assess 
thyroid dysfunction (thyroid-stimulating hormone (TSH)), which 
may aggravate HF. They may also provide other useful information 
related to the aetiology of HF (e.g. elevated blood glucose levels, 
suggesting the diagnosis of diabetes).
4.2 Further evaluation
Patients with HF-REF who are referred to a cardiologist may be 
further evaluated with:
• ambulatory electrocardiographic monitoring (Holter)
• myocardial perfusion/ischaemia/viability imaging (echocardio-
graphy, cardiovascular magnetic resonance imaging (CMR), single-
photon emission computed tomography (SPECT) or positron 
emission tomography (PET)) 
• coronary angiography
• left and right heart haemodynamic assessments 
• exercise testing 
• genetic testing.
5. Management of HF
5.1 Objectives
To make patients feel better; to reduce hospitalisations (new and 
recurrent); and to prolong survival. It is now recognised that 
preventing HF hospitalisation is important for patients and healthcare 
systems. 
Table 1. New York Heart Association classification of HF
Class Description
I Patient with cardiac disease, but no limitation on 
ordinary physical activity
II Comfortable at rest, ordinary activity results in 
symptoms (slight limitation)
III Comfortable at rest, less than ordinary activity results 
in symptoms (marked limitation)
IV Symptomatic at rest, increased discomfort with any 
physical activity
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5.2 Pharmacological therapies of HF-REF
5.2.1 Symptomatic relief
5.2.1.1 Diuretics
Diuretics are recommended to relieve dyspnoea and oedema in 
patients with signs and symptoms of congestion. Their effects on 
mortality and morbidity have, however, not been studied. 
Loop diuretics produce a more intense and shorter diuresis than 
thiazides, which cause a more gentle and prolonged diuresis. Loop 
diuretics are usually preferred to thiazides in HF-REF.
The aim of using diuretics is to achieve and maintain euvolaemia 
(the patient’s ‘dry weight’) with the lowest dose possible. This means 
that the dose must be adjusted, particularly after restoration of dry 
body weight, to avoid the risk of dehydration leading to hypotension 
and renal dysfunction. The diuretic dose may have to be reduced after 
angiotensin-converting enzyme inhibitors (ACEIs) are introduced. It 
is important to replace serum K⁺ accordingly (1 200 mg potassium 
salt per 40  mg furosemide). Potassium supplementation needs to 
be reduced in patients on concomitant MRAs. Intravenous (IV) 
diuretic should be used when there is marked volume overload and/
or pulmonary oedema.
Many patients can be trained to self-adjust their diuretic dose, 
based on monitoring of symptoms/signs of congestion and daily 
weight measurements. Patients should be encouraged to restrict fluid 
intake (<1.5 l/day).
5.2.1.1.1 Diuretic resistance 
If a patient does develop resistance to a high dose of loop diuretic, 
the addition of a thiazide (hydrochlorothiazide) or thiazide-like 
(metolazone) diuretic (1 hour before administration of the loop 
diuretic) often results in a remarkable synergistic effect. These 
patients should ideally be referred, as large fluid shifts occur together 
with electrolyte changes. Careful patient and laboratory monitoring 
is necessary.
Refer to Table 2 for the recommended diuretics and their doses. 
Please note that metolazone is available in South Africa on Section 21.
5.2.1.2 Digoxin
Digoxin is recommended in patients on conventional therapy with 
symptomatic HF and rapid AF to slow the ventricular response rate. 
Digoxin may be used in HF-REF and sinus rhythm if patients are still 
symptomatic on full tolerated background therapy to reduce the risk 
of HF hospitalisation. 
Toxic drug levels can occur especially in the elderly, patients with 
poor renal function, in the presence of hypokalaemia, active coronary 
ischaemia and low body weight (recommended dose is 0.125  mg 
at night). Always be aware when introducing other drugs of their 
possible interaction with digoxin metabolism. Digoxin levels should 
be monitored carefully and one should aim for a therapeutic blood 
level of 0.5 - 0.8 ng/ml taken 12 hours after the last dose.
5.2.2 Symptomatic relief and mortality benefit
Three neurohumoral antagonists, an ACEI (or angiotensin receptor 
blocker (ARB)), a beta-blocker (BB) and MRAs are fundamentally 
important in modifying the course of HF-REF and should be 
considered in every patient. The order of initiation between an ACEI 
and BB is not crucial and either can be started first. 
5.2.2.1 ACEIs
An ACEI is recommended for all patients with HF-REF to reduce the 
risk of HF hospitalisation and premature death.
ACEIs occasionally cause worsening of renal function, hyperkalaemia, 
symptomatic hypotension, cough, and, rarely, angioedema. An ACEI 
should be used with caution in patients with inadequate renal function 
(serum creatinine ≥221 mmol/l or estimated glomerular filtration rate 
(eGFR) ≤30 ml/min/1.73 m2). An ACEI should not be used in patients 
with an abnormal serum potassium level >5.2 mmol/l.
Therapy with ACEIs should always be initiated at a low dose 
(Table 3). If a patient develops symptomatic hypotension or pre-renal 
azotaemia, then decreasing or temporarily withdrawing the diuretic 
(24 - 48 hours) is preferable to discontinuing the ACEI. 
Dosage titration:
• Following 24 - 48 hours of therapy, the patient should be contacted 
to ask about possible side-effects.
• Within one week of initiation of therapy, the patient should have 
the following checked: blood pressure (BP), urea, creatinine and 
electrolytes.
• If side-effects occur, treatment should be changed. Reduce diuretic 
dose if symptomatic hypotension or deteriorating renal function 
Table 2. Doses of diuretics commonly used to treat HF (with and without a preserved ejection fraction, chronic and acute)[1]
Diuretics Initial dose (mg) Usual daily dose (mg)
Loop diuretics*
Furosemide
Bumetanide
Torasemide
20 - 40
0.5 - 1.0
5 - 10
40 - 420
1 - 5
10 - 20
Thiazides†
Bendroflumethiazide
Hydrochlorothiazide
Metolazone
Indapamide‡
2.5
25
2.5
2.5
2.5 - 10
12.5 - 100
2.5 - 10
2.5 - 5
Potassium-sparing diuretics§
Spironolactone/eplerenone
Amiloride
Triamterene
+ACEI/ARB
12.5 - 25
2.5
25
-ACEI/ARB
50
5
50
+ACEI/ARB
50
5 - 10
100
-ACEI/ARB
100 - 200
10 - 20
200
HF = heart failure; ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; MRA = mineralocorticoid receptor antagonist.
* Oral or intravenous; dose may need to be adjusted according to volume status/weight; excessive doses may cause renal impairment and ototoxicity.† Do not use thiazides if estimated glomerular filtration rate <30 ml/min, except when prescribed synergistically with loop diuretics.‡Indapamide is a non-thiazide sulphonamide.§ An MRA, i.e. spironolactone/eplerenone, is always preferred. Amiloride and triamterene should not be combined with an MRA.
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is found. Decrease potassium replacement if serum potassium is 
raised or decrease/stop potassium-sparing diuretics.
• An increase in serum creatinine need not require discontinuation 
of the ACEI.
• Dosage of ACEIs should be up-titrated over 2 - 4 weeks in 
ambulatory patients to target doses.
• ACEI cough (cough related to HF having been excluded), if severe, 
usually requires withdrawal of the ACEI.
5.2.2.2 BBs
A BB is recommended, in addition to an ACEI (or ARB if an ACEI is 
not tolerated), for all patients with HF-REF to reduce the risk of HF 
hospitalisation and the risk of premature death. The ideal candidate 
should not be on IV medications, should have no signs of marked 
fluid retention and be on stable doses of standard medication. Refer 
to Table 3 and note that only carvedilol and bisoprolol are widely 
available in South Africa. 
5.2.2.3 MRAs
Spironolactone and eplerenone (Table  3) block receptors that bind 
aldosterone and other corticosteroids, and are best characterised as 
MRAs. Both can cause hyperkalaemia and worsening renal function, 
especially in the elderly. 
An MRA is recommended for all patients with persisting symptoms 
(NYHA class II - IV) despite treatment with an ACEI (or an ARB 
if an ACEI is not tolerated) and a BB, to reduce the risk of HF 
hospitalisation and the risk of premature death.
They should only be used in patients with adequate renal function 
(creatinine ≤221 mmol/l or ≤2.5 mg/dl or eGFR ≥30 ml/min/1.73 m2) 
and a normal serum potassium concentration (K+ 3.5 - 5.2 mmol/l); 
if either is used, serial monitoring of serum electrolytes and renal 
function is mandatory. 
Potassium and creatinine should be monitored 5 days after starting 
treatment and be repeated 1 week later or on further titrations. The 
recommended dose for either spironolactone or eplerenone is: a starting 
dose of 25 mg once daily and a target dose 25 - 50 mg once daily.
Although spironolactone is first choice based on cost, patients 
who develop gynaecomastia should be switched to eplerenone. The 
combination of spironolactone and digoxin is synergistic for this 
complication.
5.2.3 Symptom relief and uncertain mortality benefit
5.2.3.1 ARBs
ARBs are recommended to reduce the risk of:
• HF hospitalisation and premature death in patients with HF-REF 
and who are unable to tolerate an ACEI because of cough (patients 
should also receive a BB and an MRA)
• HF hospitalisation in patients with HF-REF and who have 
persisting symptoms (NYHA class II - IV) despite treatment with 
an ACEI and a BB, and who are unable to tolerate an MRA. 
5.2.3.2 Ivabradine 
Ivabradine is a drug that inhibits the If channel in the sinus node. 
Its only known pharmacological effect is to slow the heart rate in 
patients in sinus rhythm (it does not slow the ventricular rate in AF).
It should be considered to reduce the risk of HF hospitalisation in 
patients in sinus rhythm with an EF ≤35% and a heart rate remaining 
at ≥70 bpm and persisting symptoms (NYHA class II - IV) despite 
treatment with an evidence-based dose of BB (or maximum tolerated 
dose below that), an ACEI (or ARB) and an MRA (or ARB).
It may be considered to reduce the risk of HF hospitalisation in 
patients in sinus rhythm with an EF ≤35% and a heart rate ≥70 bpm 
who are unable to tolerate a BB. Patients should also receive an ACEI 
(or ARB) and an MRA (or ARB).
The South African Medicines Control Council (MCC) labelling, 
however, states that: ‘Ivabradine is indicated in adults in sinus 
rhythm with mild to moderate (NYHA class II and III) symptomatic 
HF whose heart rate is ≥77  bpm to reduce cardiovascular events 
(cardiovascular mortality or hospitalisation for worsening HF), in 
combination with standard therapy including BB or when BB are 
contraindicated or not tolerated’.
5.2.3.3 Combination of hydralazine and nitrates 
This may be considered as an alternative to an ACEI or ARB, if 
neither is tolerated, to reduce the risk of HF hospitalisation and risk 
of premature death in patients with HF-REF. Patients should also 
receive a BB and an MRA.
It should be considered to reduce the risk of HF hospitalisation 
and risk of premature death in patients with HF-REF and persisting 
symptoms (NYHA class II - IV) despite treatment with a BB, ACEI 
(or ARB) and an MRA (or ARB).
Recommended dosages of the combinations: 
• hydralazine 10 - 25 mg 3 times daily, increased to 75 mg 3 times 
daily
• isosorbide dinitrate 10 mg 3 times daily, increased to 40 mg 3 times 
a day
Table 3. Evidence-based doses of disease-modifying drugs 
used in key randomised trials in HF (or after MI)[1]
Dose (mg)
Starting Target
ACEI
Captopril*
Enalapril 
Lisinopril† 
Ramipril 
Trandolapril* 
6.25 t.i.d. 
2.5 b.i.d. 
2.5 - 5.0 o.d. 
2.5 o.d. 
0.5 o.d. 
50 t.i.d.
10 - 20 b.i.d.
20 - 35 o.d.
5 b.i.d.
4 o.d.
Beta-blocker
Bisoprolol 
Carvedilol 
Metoprolol succinate (CR/XL)
Nebivolol‡ 
1.25 o.d. 
3.125 b.i.d. 
12.5/25 o.d. 
1.25 o.d. 
10 o.d.
25 - 50 b.i.d.
200 o.d.
10 o.d.
ARB
Candesartan
Valsartan 
Losartan†,‡
4/8 o.d.
40 b.i.d. 
50 o.d. 
32 o.d.
160 b.i.d.
150 o.d.
MRA
Eplerenone 
Spironolactone 
25 o.d. 
25 o.d.
50 o.d.
25 - 50 o.d.
HF = heart failure; MI = myocardial infarction; ACEI = angiotensin-converting enzyme 
inhibitor; CR/XL = controlled-release/extended-release; ARB = angiotensin receptor 
blocker; MRA = mineralocorticoid receptor antagonist; b.i.d. = twice daily; o.d. = once 
daily; t.i.d = three times daily.
* Indicates an ACEI where the dosing target is derived from post-myocardial infarction trials.† Indicates drugs where a higher dose has been shown to reduce morbidity-mortality 
compared with a lower dose of the same drug, but there is no substantive placebo-
controlled randomised controlled trial and the optimum dose is uncertain.‡ Indicates a treatment not shown to reduce cardiovascular or all-cause mortality in patients 
with HF or after acute MI (or shown to be non-inferior to a treatment that does).
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• isosorbide mononitrate 10 mg twice a day, increased to 20 - 40 mg 
twice a day.
5.3 Ventricular rate control in AF
For ventricular rate control in patients with HF-REF and AF, a BB is 
preferred over digoxin, as the latter does not provide adequate rate 
control during exercise. The combination of digoxin and a BB is more 
effective than a BB alone in controlling the ventricular rate at rest.
Non-dihydropyridine calcium channel blockers (CCBs) verapamil 
and diltiazem are not recommended in patients with HF-REF as they 
increase mortality.
5.4 Oral anticoagulants
Warfarin is not routinely required in patients with HF-REF unless 
they have AF or LV mural thrombus.
6.  Non-pharmacological therapies 
of HF-REF 
6.1 Implantable cardioverter-defibrillator (ICD)
Approximately half of the deaths in patients with HF, especially in 
those with milder symptoms, occur suddenly and many, if not most, 
of these are related to ventricular arrhythmias.
Prevention of sudden death is therefore an important goal in 
HF. While the key disease-modifying neurohumoral antagonists 
mentioned earlier reduce the risk of sudden death, they do not 
abort it. Specific anti-arrhythmic drugs do not decrease this risk 
(and may even increase it). Therefore, ICDs play an important role 
in reducing the risk of death from ventricular arrhythmias and 
bradyarrhythmias.
6.1.1 Primary prevention of sudden cardiac death
An ICD is recommended in a patient with symptomatic HF (NYHA 
class II - III) and an EF ≤35% despite ≥3 months of treatment with 
optimal pharmacological therapy, who is expected to survive for 
>1  year with good functional status, to reduce the risk of sudden 
death. ICD implantation should be delayed for >40  days following 
MI, since LV function/EF may improve during this interval.
6.1.2 Secondary prevention of sudden cardiac death
ICDs reduce mortality in survivors of cardiac arrest and in patients 
with sustained symptomatic ventricular arrhythmias. Consequently, 
an ICD is recommended in such patients, irrespective of EF, with 
good functional status, a life expectancy of >1 year, and where the 
intent is to increase survival.
6.2 CRT
The indications for CRT are summarised in Tables 4 and 5.
6.3 Patients in permanent AF
CRT pacemaker (CRT-P)/CRT defibrillator (CRT-D) may be 
considered in patients in NYHA functional class III or ambulatory 
class IV with a QRS duration ≥120  ms and an EF ≤35%, who are 
expected to survive with good functional status for >1 year, to reduce 
the risk of HF worsening, if the patient:
• requires pacing because of an intrinsically slow ventricular rate
• is pacemaker-dependent as a result of AV nodal ablation.
In patients with an indication for conventional pacing and no other 
indication for CRT: in patients who are expected to survive with good 
Table 4. Recommendations for use of CRT where the evidence is strong – patients in sinus rhythm with NYHA functional class III 
and ambulatory class IV HF and a persistently reduced EF, despite optimal pharmacological therapy[1]
Recommendations Class Level*
LBBB QRS morphology
 CRT-P/CRT-D is recommended in patients in sinus rhythm with a QRS duration of ≥120 ms, LBBB QRS morphology, 
and an EF ≤35%, who are expected to survive with good functional status for >1 year, to reduce the risk of HF 
hospitalisation and risk of premature death
I A[2,3]
Non-LBBB QRS morphology
 CRT-P/CRT-D should be considered in patients in sinus rhythm with a QRS duration of ≥150 ms, irrespective of QRS 
morphology, and an EF ≤35% who are expected to survive with good functional status for >1 year, to reduce the risk of 
HF hospitalisation and the risk of premature death 
IIa A[2,3]
CRT = cardiac resynchronisation therapy; NYHA = New York Heart Association; HF = heart failure; EF = ejection fraction; LBBB = left bundle branch block; CRT-D = CRT defibrillator; 
CRT-P = CRT pacemaker; RCT = randomised clinical trial.
* Level of evidence: A = data derived from multiple RCTs or meta-analyses; B = data derived from a single RCT or large non-randomised studies; C = consensus of opinion of the experts and/or 
small studies, retrospective studies, registries.
Table 5. Recommendations for the use of CRT where the evidence is strong – patients in sinus rhythm with NYHA functional 
class II HF and a persistently reduced EF, despite optimal pharmacological therapy[1]
Recommendations Class Level*
LBBB QRS morphology
 CRT, preferably CRT-D, is recommended in patients in sinus rhythm with a QRS duration of ≥130 ms, LBBB QRS 
morphology, and an EF ≤30%, who are expected to survive for >1 year with good functional status, to reduce the risk 
of HF hospitalisation and the risk of premature death
I A[4,5]
Non-LBBB QRS morphology
 CRT, preferably CRT-D, should be considered in patients in sinus rhythm with a QRS duration of ≥150 ms, 
irrespective of QRS morphology, and an EF ≤30%, who are expected to survive for >1 year with good functional status, 
to reduce the risk of HF hospitalisation and the risk of premature death
IIa A[4,5]
CRT = cardiac resynchronisation therapy; NYHA = New York Heart Association; HF = heart failure; EF = ejection fraction; LBBB = left bundle branch block; CRT-D = CRT defibrillator; 
CRT-P = CRT pacemaker; RCT = randomised clinical trial.
*Level of evidence: refer to Table 4.
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functional status for >1 year, CRT should be considered in those in 
NYHA functional class II - IV with an EF ≤35%, irrespective of QRS 
duration, to reduce the risk of worsening of HF.
7. Hypertension
Hypertension is associated with an increased risk of developing HF; 
antihypertensive therapy markedly reduces the incidence of HF (with 
an exception of alpha-adrenoceptor blockers, which are less effective 
than other antihypertensives in preventing HF).
Negatively inotropic CCBs (i.e. diltiazem and verapamil) should 
not be used to treat hypertension in patients with HF-REF, and 
moxonidine should also be avoided in patients with HF-REF as it is 
associated with increased mortality.
If BP is not controlled with an ACEI (or ARB), a BB, MRA and a 
diuretic, then a choice from hydralazine/amlodipine/felodipine can 
be made. Short-acting nifedipine is contraindicated in HF-REF and 
no data are available on long-acting nifedipine.
8. Heart transplantation
Heart transplantation is an accepted treatment for end-stage HF. 
Although controlled trials have never been conducted, there is 
consensus that transplantation – provided that proper selection criteria 
are applied – significantly increases survival, exercise capacity, quality 
of life, and return to work compared with conventional treatment.
Apart from the shortage of donor hearts, the main challenges in 
transplantation are the consequences of the limited effectiveness and 
complications of immunosuppressive therapy in the long term (i.e. 
antibody-mediated rejection, infection, hypertension, renal failure, 
malignancy and coronary artery vasculopathy). 
There are four heart transplantation centres in South Africa: two 
in Cape Town (Christiaan Barnard Memorial and Groote Schuur 
hospitals), one in Johannesburg (Milpark Hospital) and one in 
Durban (Ethekwini Hospital and Heart Centre). 
8.1. Indications for heart transplantation
8.1.1 Absolute indications in appropriate patients
These include:
• Haemodynamic compromise due to HF:
• refractory cardiogenic shock
• documented dependence on IV inotropic support to maintain 
adequate organ perfusion
• peak oxygen consumption per unit time (VO2) <10 ml/kg/min 
with achievement of anaerobic metabolism.
• Severe symptoms of ischaemia that consistently limit routine 
activity and are not amenable to coronary artery bypass surgery or 
percutaneous coronary intervention.
• Recurrent symptomatic ventricular arrhythmias refractory to all 
therapeutic modalities.
8.1.2 Relative indications
• Peak VO2 11 - 14 ml/kg/min (or 55% predicted) and major limi-
tation of the patient’s daily activities
• Recurrent unstable ischaemia not amenable to other interventions
• Recurrent instability of fluid balance/renal function not due to 
patient non-compliance with medical regimen.
8.1.3 Insufficient indications
• Low LVEF
• History of functional class III or IV symptoms of HF
• Peak VO2 >15  ml/kg/min (and >55% predicted) without other 
indications.
8.1.4  Haemodynamic criteria for evaluation of candidates for 
transplantation
• Pulmonary artery hypertension and elevated pulmonary 
vascular resistance (PVR) should be considered as a relative 
contraindication to cardiac transplantation when the PVR is 
>5 Wood units or the pulmonary vascular resistance index 
(PVRI) is >6 or the transpulmonary gradient (TPG) exceeds 
16 - 20 mmHg
• If the PAS exceeds 60 mmHg in conjunction with any 1 of the 
preceding 3 variables, the risk of right HF and early death is 
increased
• If the PVR can be reduced to <2.5 with a vasodilator but the 
systolic BP falls <85  mmHg, the patient remains at high risk of 
right HF and mortality after heart transplantation.
9. Exercise training
Several systematic reviews and meta-analyses of small studies have 
shown that physical conditioning by exercise training improves 
exercise tolerance, health-related quality of life, and HF hospitalisation 
rates in patients with HF. 
10.  Organisation of care and 
multidisciplinary management 
programmes
The goal of management of HF is to provide a ‘seamless’ system of 
care, embracing both the community and hospital, to ensure that the 
management of every patient is optimal, from the beginning to the 
end of their healthcare journey.
To achieve this goal, other services, such as cardiac rehabilitation 
and palliative care, must be integrated into the overall provision for 
patients with HF. 
Fundamental to the delivery of this complete package of care are 
multidisciplinary management programmes designed to improve 
outcomes through structured follow-up with patient education, 
optimisation of medical treatment, psychosocial support, and 
improved access to care. 
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